|Bid||6.61 x 1000|
|Ask||7.32 x 1100|
|Day's Range||6.84 - 7.33|
|52 Week Range||6.84 - 24.48|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 8, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.82|
NEW ORLEANS , June 14, 2019 /PRNewswire/ -- Former Attorney General of Louisiana , Charles C. Foti, Jr., Esq. , a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF ...
Investment banker Barclays announced it has initiated coverage of 20 U.S. specialty pharmaceuticals stocks.But which 20 stocks within this sector are we talking about today? They include generic drugs companies Mylan (MYL), which Barclays rates Overweight (i.e. 'buy') and Teva Pharmaceutical Industries (TEVA), which the analyst rates Underweight (i.e. 'sell'), as well as: * Amneal Pharmaceuticals (AMRX) * Endo International (ENDP) * Reddy's Laboratories (RDY) * and Mallinckrodt plc (MNK)Each of which is rated Equal weight (i.e. 'hold').Within the animal health sector (i.e. veterinary medicine), Barclays initiates coverage with Overweight ratings on Zoetis (ZTS) and Kindred Biosciences (KIN), but gives Phibro Animal Health Corporation (PAHC) an Underweight rating.Among developmental and commercial stage companies "with unique products & segments," Barclays has two 'sells' -- Allergan (AGN) and Evolus (EOLS) -- and one hold: Ligand Pharmaceuticals (LGND). As for Barclays' 'buy' ratings, it rates the following companies Overweight ratings: * AMAG Pharmaceuticals (AMAG) * Jazz Pharmaceuticals (JAZZ) * Osmotica Pharmaceuticals (OSMT) * Coherus BioSciences (CHRS) * Pacira BioSciences (PCRX) * Revance Therapeutics (RVNC) * Bausch Health Companies (BHC) * and Foamix Pharmaceuticals (FOMX)Today, we really only have time to glance at just one of these stocks: Rehovot, Israel-based Foamix.Foamix is a late clinical-stage specialty pharmaceutical company focusing on foam-based medications for the treatment of acne and rosacea. Foamix stands out in this report primarily by virtue of the extremely high hopes Barclays' has for it, namely, valued at just $2.53 per share today, Barclays believes that within a year, Foamix stock will be selling for $10 -- a four-bagger in just one year.Why is Barclays so optimistic? As the analyst explains, Foamix is on the cusp of becoming a "commercial stage company" -- i.e. a company with actual revenue from sales, a rarity in small drugs stocks -- thanks to its topical Minocycline product for acne and rosacea. Designated "FMX-101" for acne treatment and "FMX-103" for rosacea, both these foam-based products "combine [the] proven efficacy of minocycline with a more tolerable side effect profile" says Barclays. From $3 million in annual revenue today, the banker predicts Foamix could do as much as $272 million in annual sales by 2025E.Considering that the entire company has a market cap of barely half that number -- $138 million -- today, Foamix at least seems to have earned its place on Barclays' list.Foamix has a few upcoming catalysts that could send its shares surging higher: * There is a scheduled PDUFA for FMX-101 on October 20, 2019. This is a key event for Foamix, as FMX-101 is its lead product in acne. * Foamix anticipates filing an NDA in mid-2019 for FMX-103 in moderate-to-severe papulopustular rosacea. * FCD-105 Phase II study initiation in mid-2019: FCD-105 is another pipeline product being evaluated in patients with acne and is a foam-based combination of minocycline and adapalene."We value Foamix on a DCF basis, assuming an 11.5% discount rate and a 3% terminal growth. We include risk adjusted pipeline values for both FMX-101 (90% probability of success) and FMX-103 (70% probability of success). We also assume base uptake of FMX-101, reaching 2025 risk-adj. sales of ~$200mm. This scenario yields a value of ~$10/share and serves as the basis for our price target," Barclays noted.Read more: Foamix (FOMX): A Beaten-Down Biotech Stock That Looks Like a Bargain Now More recent articles from Smarter Analyst: * Village Farms (VFF) Has a Lot Going for It * Hexo Has Difficult Days Ahead, Analyst Says * Square (SQ) Growth Slowing, But Evercore Remains Bullish on the Stock * This Analyst Sticks with His Buy Rating on Aphria (APHA) Stock, But Trims Price Target
Amneal Pharmaceuticals, Inc. today announced that members of management will participate at the following upcoming investor conferences:
Teva Pharmaceutical and Mylan could be on the hook for billions in damages after a lawsuit accused pharmaceutical companies of colluding to fix generic drug prices, an analyst said Friday.
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Amneal Pharmaceuticals, Inc. (AMRX). For many years, the Company, (formerly Impax Laboratories Inc.), which develops, manufactures, and markets bioequivalent, generic, pharmaceutical products, has been embroiled in investigations and litigation by state and federal authorities and relating to claims that it colluded with other competitor companies in a price-fixing scheme resulting in exponential price increases of certain products. The Company has been sued in a securities class action lawsuit for failing to disclose material information to shareholders, violating federal securities laws, which is ongoing.
Amneal Pharmaceuticals, Inc. today announced that members of management will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference in New York on Tuesday, May 21, 2019 at 11:00 a.m.
NEW YORK , May 13, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Amneal Pharmaceuticals, Inc. ("Amneal" or the "Company") ...
Amneal (AMRX) delivered earnings and revenue surprises of -22.22% and 2.66%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Bridgewater, New Jersey-based company said it had a loss of 37 cents per share. Earnings, adjusted for one-time gains and costs, were 14 cents per share. The results missed Wall Street expectations. ...
Hedge funds are known to underperform the bull markets but that's not because they are bad at investing. Truth be told, most hedge fund managers and other smaller players within this industry are very smart and skilled investors. Of course, they may also make wrong bets in some instances, but no one knows what the […]
Amneal Pharmaceuticals, Inc. will release its first quarter 2019 financial results on Thursday, May 9, 2019, prior to the open of the U.S. financial markets. The Company will host a conference call and live webcast with the investment community at 8:30 a.m., Eastern Time on May 9, 2019.
Amneal Pharmaceuticals, Inc. (AMRX), today announced that the company has appointed Pradeep Bhadauria as Chief Scientific Officer (CSO), effective immediately. Pradeep brings significant R&D expertise to Amneal, including more than 20 years leading the development capabilities for several leading generic and specialty pharmaceutical companies.
BRIDGEWATER, N.J., April 1, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has entered into an agreement with Zentiva Group a.s., under which Zentiva has acquired Creo Pharmaceuticals Ltd., a subsidiary of Amneal that operates the company's commercial operations in the United Kingdom. "We believe that the value created by our commercial operations in the UK will be better maximized by Zentiva, which will gain additional products and enhanced competitive market share position as a result of this transaction," said Rob Stewart, President and CEO of Amneal.
President and CEO of Amneal Pharmaceuticals Inc (NYSE:AMRX) Robert A Stewart bought 17,000 shares of AMRX on 03/12/2019 at an average price of $11.92 a share.
BRIDGEWATER, N.J., March 12, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (AMRX), today announced that it has launched its generic version of Exelon® Patch (Rivastigmine Transdermal System), 4.6 mg/24 hours, 9.5 mg/24 hours, and 13.3 mg/24 hours. The Company received FDA approval of its Rivastigmine Transdermal System in January 2019, and has received final approval on 10 Abbreviated New Drug Applications this year. "We are pleased to have received approval on and launched the company's first transdermal product, which demonstrates our commitment to develop and bring to market complex generic products," said Rob Stewart, President and CEO of Amneal.
BRIDGEWATER, N.J. , March 6, 2019 /PRNewswire/ -- Amneal Pharmaceuticals, Inc. (NYSE: AMRX) today announced that members of management will participate in a fireside chat at the Barclays Global Healthcare ...
Amneal Pharmaceuticals Inc (NYSE:AMRX) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018.
‒ Q4 2018 Net Revenue of $498 Million ; GAAP Loss per share of $0.07 ; Combined Adjusted Diluted EPS(1) of $0.33 ‒ ‒ Full Year 2018 Net Revenue of $1.66 Billion ; GAAP Loss per share of $0.16 ; Combined ...